en Original/Research Article <p style="text-align: justify;"><span style="font-size:12pt"><span style="line-height:150%"><span new="" roman="" style="font-family:" times=""><strong><span style="font-size:10.5pt"><span style="line-height:150%">Introduction</span></span></strong><span style="font-size:10.5pt"><span style="line-height:150%">: Breast cancer is the most common metastatic malignancy and the second leading cause of death in women. Recently, extremely low-frequency electromagnetic fields (ELF-EMFs) seem to modulate the rate of proliferation and enhance apoptosis and are considered as an emerging approach to cancer therapy. Despite recent success in the electromagnetic fields, the results are still neither definitive nor even contradictory.&nbsp;&nbsp;<br> <b><span style="color:#1d1d1b">Methods: </span></b><span style="color:#1d1d1b">In this </span></span></span><span style="font-size:10.5pt"><span style="line-height:150%"><span arial="" ms="" style="font-family:" unicode=""><span style="color:#1d1d1b"><span style="letter-spacing:-.2pt">st</span></span></span></span></span><span style="font-size:10.5pt"><span style="line-height:150%"><span style="color:#1d1d1b"><span style="letter-spacing:-.2pt">udy</span></span></span></span><span style="font-size:10.5pt"><span style="line-height:150%"><span style="color:#1d1d1b"><span style="letter-spacing:-.15pt">,</span></span></span></span><span style="font-size:10.5pt"><span style="line-height:150%"><span style="color:#1d1d1b"> induction of apoptosis was considered as one of the possible&nbsp;mechanisms of ELF-EMFs on cancer inhibition. Brea</span></span></span><span style="font-size:10.5pt"><span style="line-height:150%"><span arial="" ms="" style="font-family:" unicode=""><span style="color:#1d1d1b">st</span></span></span></span><span style="font-size:10.5pt"><span style="line-height:150%"><span style="color:#1d1d1b"> cancer cell lines were exposed to a 1 Hz, 100mT ELF-EMF (2h/day) for five days. the apoptosis rare of both the exposure and sham exposure groups was determined by flow cytometry. The expression&nbsp;levels of Bax and Bcl-2 were evaluated by real-time PCR.</span></span></span><br> <span style="font-size:10.5pt"><span style="line-height:150%"><b><span style="color:#1d1d1b">Results: </span></b><span style="color:#1d1d1b">The mRNA expression levels of Bax were increased; while the expression of Bcl-2 showed a decrease in MDA-MB231 cells exposed to 1Hz EMF compared with sham exposure. Moreover, the ratio of Bax/Bcl2 was significantly increased in&nbsp;comparison to the sham exposure. The increased Bax/Bcl-2 ratio induces cell apoptosis.<br> <b>Conclusions: </b>It is sugge</span></span></span><span style="font-size:10.5pt"><span style="line-height:150%"><span arial="" ms="" style="font-family:" unicode=""><span style="color:#1d1d1b">st</span></span></span></span><span style="font-size:10.5pt"><span style="line-height:150%"><span style="color:#1d1d1b">ed that ELF-EMF is a new adjuvant therapeutical method that may contribute to anti-cancer and cancer therapy research.</span></span></span></span></span></span></p> <div style="text-align: justify;"><br> <span style="font-size:11pt"><span style="punctuation-wrap:simple"><span new="" roman="" style="font-family:" times=""><span style="font-size:3.5pt"></span></span></span></span></div> Breast Cancer, Apoptosis, Electromagnetic Fields, Bax/Bcl-2 1 7 http://mcijournal.com/browse.php?a_code=A-10-32-2&slc_lang=en&sid=1 Maryam Moori 10031947532846003270 10031947532846003270 No Department of Biology, Science and Research Branch, Islamic Azad Univer- sity, Tehran, Iran Dariush Norouzian 10031947532846003271 10031947532846003271 No Pilot Nanobiotechnology Department, Pasteur Institute of Iran, Tehran, Iran Parichehr Yaghmaei 10031947532846003272 10031947532846003272 No Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran Leila Farahmand laylafarahmand@gmail.com 10031947532846003273 10031947532846003273 Yes 3Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran